Department of Radiology and Imaging Sciences, Emory University School of Medicine, Atlanta, Georgia.
Department of Radiology and Imaging Sciences, Emory University School of Medicine, Atlanta, Georgia.
J Vasc Interv Radiol. 2023 Jul;34(7):1226-1234. doi: 10.1016/j.jvir.2023.02.030. Epub 2023 Mar 21.
To evaluate the differences in safety, effectiveness, and dosimetry between glass-based and resin-based ablative yttrium-90 (Y) transarterial radioembolization (TARE) of hepatocellular carcinoma (HCC).
Using the modified Response Evaluation Criteria in Solid Tumors and Common Terminology Criteria for Adverse Events, both tumor response and adverse events (AEs) were assessed at 3 months after Y-TARE. Post procedure Y-bremsstrahlung single-photon emission computed tomography/computed tomography voxel-based dosimetry analysis was used to create tumor dose (TD) and normal tissue dose (NTD) volume histograms, and to calculate tumor particle loading and specific activity. The TD and NTD receiver operating characteristic curves evaluated the dose threshold able to predict objective (partial or complete) and complete tumor responses in addition to any-grade and grade ≥3 AE incidences. The chi-square test and Student t-test were used to assess variable differences where appropriate.
Between 2019 and 2020, 81 patients with HCC (20 in the resin-based cohort and 61 in the glass-based cohort) underwent ablative Y-TARE. The resin-based cohort had more males (89% vs 65%, P = .03), lower tumor-to-normal ratio (1.81 ± 0.39 vs 2.22 ± 0.94, P = .03), higher tumor particle loading (40,172 particles/mL ± 28,039 vs 17,081 particles/mL ± 12,555, P = .0001), lower specific activity (158 Bq/particle ± 3 vs 1,058 Bq/particle ± 331, P = .001), and lower mean TD (308 Gy ± 210 vs 794 Gy ± 523, P = .0002) than the glass-based cohort. No significant differences in baseline characteristics or posttreatment AEs were noted. The overall objective and complete response rates were 85% (95% resin-based vs 82% glass-based; P = .1) and 65% (95% resin-based vs 56% glass-based; P = .003), respectively. The mean TD thresholds able to predict the objective and complete responses were 176 Gy and 247 Gy for resin-based radioembolization and 290 Gy and 481 Gy for glass-based radioembolization, respectively. A maximum NTD of 999 Gy predicted any-grade AEs in glass-based ablative Y-TARE.
Compared with glass-based ablative Y-TARE, resin-based ablative Y-TARE can offer comparable safety and effectiveness profiles for patients with HCC. The impact of the significantly different tumor particle loading, particle specific activities, and delivered TDs on tumor response outcomes merits further investigation.
评估玻璃基和树脂基放射性栓塞钇 90(Y)经动脉放射性栓塞(TARE)治疗肝细胞癌(HCC)的安全性、有效性和剂量学差异。
使用改良的实体瘤反应评估标准和常见不良事件术语标准,在 Y-TARE 治疗后 3 个月评估肿瘤反应和不良事件(AE)。采用术后 Y-韧致辐射单光子发射计算机断层扫描/计算机断层扫描体素剂量测定分析,制作肿瘤剂量(TD)和正常组织剂量(NTD)体积直方图,并计算肿瘤颗粒负荷和比活度。TD 和 NTD 接收器操作特征曲线评估能够预测客观(部分或完全)和完全肿瘤反应以及任何等级和等级≥3AE 发生率的剂量阈值。适当情况下使用卡方检验和学生 t 检验评估变量差异。
2019 年至 2020 年间,81 例 HCC 患者(树脂基队列 20 例,玻璃基队列 61 例)接受了消融性 Y-TARE。树脂基队列中男性比例更高(89%比 65%,P=.03),肿瘤-正常比值更低(1.81±0.39 比 2.22±0.94,P=.03),肿瘤颗粒负荷更高(40172 个/mL±28039 比 17081 个/mL±12555,P=.0001),比活度更低(158Bq/个±3 比 1058Bq/个±331,P=.001),平均 TD 更低(308Gy±210 比 794Gy±523,P=.0002)。两组基线特征或治疗后 AE 无显著差异。总体客观和完全反应率分别为 85%(树脂基 95%比玻璃基 82%;P=.1)和 65%(树脂基 95%比玻璃基 56%;P=.003)。预测树脂基放射性栓塞客观和完全反应的平均 TD 阈值分别为 176Gy 和 247Gy,预测玻璃基放射性栓塞客观和完全反应的平均 TD 阈值分别为 290Gy 和 481Gy。玻璃基消融性 Y-TARE 中,最大 NTD 为 999Gy 可预测任何等级的 AE。
与玻璃基消融性 Y-TARE 相比,树脂基消融性 Y-TARE 可为 HCC 患者提供相似的安全性和有效性。肿瘤颗粒负荷、颗粒比活度和给予的 TD 显著不同对肿瘤反应结果的影响值得进一步研究。